SNPX | tickerfilter.com

Fundamental analysis

17%

Profitability 0%

Dept financing 36%

Liquidity 50%

Performance 20%

Company vs Stock growth

N/A

3.000 2.670

-0.330 -11%

+ Add row to compare

Performance

5 Days

-11.67%

1 Month

-28.65%

3 Months

-44.61%

6 Months

-32.49%

1 Year

-62.80%

2 Year

147.53%

Key data

Stock price

$2.00

P/E Ratio

0.00

DAY RANGE

$1.84 - $2.04

EPS

-$3.81

52 WEEK RANGE

$1.84 - $5.38

52 WEEK CHANGE

-$59.41

MARKET CAP

4.704 M

YIELD

N/A

SHARES OUTSTANDING

1.314 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$15,474

AVERAGE 30 VOLUME

$10,679

Company detail

CEO: Alan J. Tuchman
Region: US
Website: synaptogen.com
Employees: 4
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Synaptogenix, Inc. focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

SNPX - Synaptogenix, Inc.